Version Française
Logo retour accueil

Last news

  • IntegraGen reports 1st half results for 2014

    IntegraGen released financial results for the half year ending on June 30, 2014.

    Read more

  • IntegraGen presents data on oncology biomarker at ESMO meeting

    IntegraGen presented data at ESMO 2014 confirming that its microRNA biomarker predicts survival in patients with metastatic colorectal cancer.

    Read more


IntegraGen's mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests for autism and oncology based on these discoveries. The company also strives to be a leader in providing cutting edge genomic services to academic researchers and life sciences companies based on it's technological expertise and scientific know how.

Autism Oncology Services
Disclaimers - Mentions légales - Crédits